RPL17 and cancer: These immunomodulatory properties have made PD-1 a major research focus in oncology, driving the development of PD-1 pathway inhibitors for various cancer treatments (Borghaei et al., 2015; Garon et al., 2015; Motzer et al., 2015; Callahan et al., 2016; Ferris et al., 2016).